Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo

Other

Hayashibara Co., Ltd.

Kaname Sugimoto

Shokichi Yuen

Toshio Miyake

Toshiyuki Sugimoto

Masashi Kurimoto

Shigetaka Okada

Sumio Kitahata

Shigeharu Yoshikawa

Yasushi Hayashibara

Mamoru Hirao

Eikichi Miyake

Ken Hayashibara

The present invention relates to a process for the production of human T-cell growth factor (abbreviated as 'hTCGF' hereinafter). More precisely, the present invention relates to an improved process for the mass-production of hTCGF, comprising transplanting human cells capable of producing hTCGF to a non-human warm-blooded animal, multiplying said cells while allowing the cells to receive the nutrient body fluid supplied from the animal, and producing hTCGF in the multiplied human cells. By the practice of the present invention, a much larger amount of hTCGF, i.e., about 2-10-fold or more larger than that obtained by conventional processes, can be easily obtained; thus, hTCGF in an amount sufficient to carry out various clinical treatments can be easily provided by the present invention.

Process for the production of human T-cell growth factor

A process for the mass production of hCSF, comprises cell fusion of human lymphoblastoid cells with any human cells capable of producing said substance, in vivo multiplication of the resultant hybridoma cells, using a non-human warm-blooded animal, and in vivo cultivation of the multiplied hybridoma cells to produce hCSF. The hCSF production according to the present process is much higher than that attained by conventional processes; thus, hCSF can be used in a sufficient amount in the prevention and treatment of human diseases.

Process for the production of human colony-stimulating factor

The present invention relates to a process for the production of human epidermal growth factor (hEGF). More precisely, the present invention relates to a process for the mass production of hEGF, comprising in vivo or in vitro multiplication of human cells capable of producing hEGF, and in vitro cultivation of the multiplied human cells to produce hEGF. The hEGF production according to the present invention is much higher than that attained by conventional processes; thus, hEGF can be obtained in a sufficient amount for use in the prevention and treatment of human diseases.

Process for the production of human epidermal growth factor

The present invention relates to a process for the production of human Multiplication-Stimulating Activity (hMSA). More precisely, the invention relates to a process for the mass production of low-cost hMSA, comprising in vivo multiplication of human cells capable of producing said substance, and subsequent in vitro production of hMSA with the multiplied human cells. hMSA production according to the present invention is much higher, about 2-50-fold higher in terms of hMSA production per cell, than that attained by conventional processes: thus, hMSA can be used in a sufficient amount in the prevention and treatment of human diseases.

Process for the production of human multiplication-stimulating activity

Human peptide hormones, such as insulin, growth hormone, prolactin, adrenocorticotropic hormone, placental lactogen, calcitonin, parathyroid hormone and thyroid stimulating hormone, are produced by implanting a human.times.human hybridoma lymphoblastoid cell line capable of producing the human peptide hormone in a non-human warm-blooded animal. After a period of time, the resultant tumor is extracted and disaggregated and then cultured in vitro under conditions appropriate to accumulate the human peptide hormone. The human.times.human hybridoma lymphoblastoid cell line is preferably formed by fusing parent human cells inherently capable of producing the human peptide hormone with a human lymphoblastoid line, preferably of leukemic origin. This process permits a substantial increase in the amount of human peptide hormone which can be produced.

Process for the production of human peptide hormones

The present invention relates to a process for the production of human urokinase. More precisely, the present invention relates to a process for the mass production of human urokinase, comprising in vivo multiplication of human cells capable of producing human urokinase, using the nutrient body fluid of a non-human warm-blooded animal, and exposure of the multiplied human cells to an urokinase inducer. The human urokinase present production according to the invention is much higher than that attained by conventional methods; thus, human urokinase can be used in sufficient amount in the prevention and treatment of human diseases.

Process for the production of human urokinase

A process for the production of an O/W emulsion for hyperalimentation comprising homogenization of a composition comprising hydrophobic substance, emulsifier, water and maltose into minute droplets of O/W emulsion. The emulsion can provide a higher caloric nutritive supplement to patients than conventional emulsions using glycerin. It is stable over a wide temperature range and it can be stored for long periods of time. The emulsion is particularly useful in emergency medical situations where enteral or parenteral hyperalimentation is required for the patient.

Flurocarbon-water emulsion for hyperalimentation containing maltose

The present invention relates to a process for the production of branching enzyme, and a method for improving the qualities of food products therewith. According to the present invention, a large amount of branching enzyme with a high specific activity can be easily obtained, and employment of the branching enzyme in food processing remarkably improves the qualities of food products without changing the desirable inherent properties of their amylaceous constituent(s); thus, said food products retain their qualities over a long period of time, prolonging extremely their shelf lives.

Process for the production of branching enzyme, and a method for

The present invention relates to a process for the production of human chorionic gonadotropin (hCG). More precisely, the invention relates to a process for the mass production of hCG, comprising in vivo multiplication of human lymphoblastoid cells capable of producing hCG, and hCG production by the multiplied human lymphoblastoid cells. The hCG production according to the invention is extremely higher, in terms of hCG production per cell, than that attained by conventional process using in vitro tissue culture; thus, hCG can be used in a sufficient amount in the prevention and treatment of human diseases.

Process for the production of human chorionic gonadotropin

The present invention relates to a process for the production of human follicle-stimulating hormone (hFSH). More precisely, the invention relates to a process for the mass production of hFSH, comprising in vivo multiplication of human cells capable of producing hFSH, and exposure of the multiplied human cells to a follicle-stimulating hormone inducer. The hFSH production according to the invention is much higher than that attained by conventional processes using in vitro tissue culture; thus, hFSH can be used in a sufficient amount in the prevention and treatment of human diseases.

Process for the production of human follicle-stimulating hormone

The present invention relates to a process for the production of human luteinizing hormone (hLH). More precisely, the invention relates to a process for the mass production of hLH, comprising in vivo multiplication of human cells capable of producing hLH, using non-human warm-blooded animal, and exposure of the multiplied human cells to a luteinizing hormone inducer. The hLH production according to the invention is extremely higher, in terms of hLH production per cell, than that attained by conventional processes using in vitro tissue culture, thus, hLH can be used in a sufficient amount in the prevention and treatment of human diseases.

Process for the production of human luteinizing hormone

The present invention relates to a process for the production of human erythropoietin. More precisely, the invention relates to a process for the mass production of human erythropoietin, comprising in vivo multiplication of human lymphoblastoid cells capable of producing human erythropoietin, and human erythropoietin production by the multiplied human lymphoblastoid cells. The human erythropoietin production according to the present invention is much higher, in terms of human erythropoietin production per cell, than that attained by conventional processes using in vitro tissue culture; thus, human erythropoietin can be used in a sufficient amount for the prevention and treatment of human diseases.

Process for the production of human erythropoietin

The present invention relates to a process which is easily applicable for industrial production of mouse interferon. Particularly, the present invention relates to a process based on the discovery that a large amount and high activity of mouse interferon is obtained by transplanting established mouse tumor cells to other warm-blooded animal body or inoculating the cells in a culture medium charged in a filter-membrane-interposed diffusion chamber which is designed and fitted up to or in the animal body so that its nutrient body fluid feeds the cells, multiplying the transplanted or inoculated cells in the warm-blooded animal body or the diffusion chamber utilizing said body fluid, and exposing the multiplied cells to the action of interferon inducer in vitro or in vivo.

Process for preparing mouse interferon

The present invention relates to a process for preparing a large amount of human interferon from human leukocytes. More precisely, the invention is based on the finding that the induced interferon activity can be easily increased by exposing human leukocyte suspension to both Type I and Type II interferon inducers. Thus the induced interferon activity is enhanced about 2-20-fold or higher than those attained with either Type I interferon inducer or Type II interferon inducer.

Process for preparing human interferon

The present invention relates to processes which are easily applicable for industrial production of Type II interferon and Type II interferon-containing agents. Particularly, the present processes are based on the invention that a large amount of high-titred Type II interferon is easily obtainable by transplanting established human cells in other warm-blooded animal body or inoculating the cells in a culture medium charged in a filter-membrane-interposed diffusion chamber which is designed and fitted in or to the animal body so that the cells can grow on its nutrient body fluid, multiplying the transplanted or inoculated cells in the warm-blooded animal body or the diffusion chamber utilizing the body fluid, then exposing the multiplied cells to the action of a Type II interferon inducer in vivo or in vitro to induce Type II interferon, and purifying and separating the induced Type II interferon. The agents containing Type II interferon obtained by the method disclosed herein are effective and superior for treating and preventing Type II interferon-sensitive diseases.

Growing community of inventors

Okayama, Japan

Kaname Sugimoto